The molecular reach of antibodies crucially underpins their viral neutralisation capacity

Nat Commun. 2025 Jan 2;16(1):338. doi: 10.1038/s41467-024-54916-5.

Abstract

Key functions of antibodies, such as viral neutralisation, depend on high-affinity binding. However, viral neutralisation poorly correlates with antigen affinity for reasons that have been unclear. Here, we use a new mechanistic model of bivalent binding to study >45 patient-isolated IgG1 antibodies interacting with SARS-CoV-2 RBD surfaces. The model provides the standard monovalent affinity/kinetics and new bivalent parameters, including the molecular reach: the maximum antigen separation enabling bivalent binding. We find large variations in these parameters across antibodies, including reach variations (22-46 nm) that exceed the physical antibody size (~15 nm). By using antigens of different physical sizes, we show that these large molecular reaches are the result of both the antibody and antigen sizes. Although viral neutralisation correlates poorly with affinity, a striking correlation is observed with molecular reach. Indeed, the molecular reach explains differences in neutralisation for antibodies binding with the same affinity to the same RBD-epitope. Thus, antibodies within an isotype class binding the same antigen can display differences in molecular reach, substantially modulating their binding and functional properties.

MeSH terms

  • Antibodies, Neutralizing* / immunology
  • Antibodies, Viral* / chemistry
  • Antibodies, Viral* / immunology
  • Antibody Affinity
  • Antigens, Viral / immunology
  • COVID-19* / immunology
  • COVID-19* / virology
  • Epitopes / immunology
  • Humans
  • Immunoglobulin G* / immunology
  • Immunoglobulin G* / metabolism
  • Kinetics
  • Protein Binding
  • SARS-CoV-2* / immunology
  • Spike Glycoprotein, Coronavirus* / chemistry
  • Spike Glycoprotein, Coronavirus* / immunology
  • Spike Glycoprotein, Coronavirus* / metabolism

Substances

  • Immunoglobulin G
  • Antibodies, Viral
  • Spike Glycoprotein, Coronavirus
  • Antibodies, Neutralizing
  • spike protein, SARS-CoV-2
  • Epitopes
  • Antigens, Viral